TumorSight Viz

TumorSight Viz is a medical image management and processing system designed to aid in the visualization and analysis of breast MRI studies for patients with early-stage or locally advanced breast cancer. It employs the science of dynamic MRI data processing, leveraging DICOM images for automated segmentation, measurements, and 3D renderings to provide clinicians with quantitative and qualitative insights comparable to expert radiologist assessments.

SimBioSys, Inc.'s TumorSight Viz, a medical image management and processing system, has been reviewed and determined to be substantially equivalent to a previously marketed device, enabling its market availability. This system is specifically intended for the visualization and analysis of breast magnetic resonance imaging (MRI) studies in patients with biopsy-proven early-stage or locally advanced breast cancer, supporting the evaluation of dynamic MR data through functions such as image registration, subtractions, measurements, 3D renderings, and reformats. The device's technological principle involves the visualization of dynamic MRI studies using DICOM format images, offering standard viewing tools, post-processing capabilities, and automated segmentation and measurements. Its performance was rigorously tested on an independent dataset of breast MRI studies from over 200 patients, with radiologist reviews establishing the ground truth. The results demonstrated that the device's automated measurements and tumor segmentation were at clinically acceptable levels, comparable to the variability observed between expert radiologists, though patient management decisions should not be based solely on the device's results.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific improvements in patient management or treatment pathways are anticipated by using TumorSight Viz's automated measurements compared to traditional manual evaluations?; How does TumorSight Viz account for potential variations in MRI acquisition protocols or scanner types across different clinical sites, and does this impact its performance?; Beyond quantitative measurements, what qualitative insights or advanced visualization features does TumorSight Viz offer that could enhance radiologists' diagnostic confidence?; Are there ongoing or planned studies to evaluate the long-term clinical utility and impact of TumorSight Viz on patient outcomes, such as treatment response monitoring or recurrence detection?; What is the learning curve for clinicians and radiologists to effectively integrate TumorSight Viz into their workflow, and what training or support is provided by SimBioSys?